169 related articles for article (PubMed ID: 36437460)
1. Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
Kim JW; Park SH; Choi SA; Kim SK; Koh EJ; Won JK; Nam SM; Phi JH
BMC Cancer; 2022 Nov; 22(1):1221. PubMed ID: 36437460
[TBL] [Abstract][Full Text] [Related]
2. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
6. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.
Northcott PA; Shih DJ; Remke M; Cho YJ; Kool M; Hawkins C; Eberhart CG; Dubuc A; Guettouche T; Cardentey Y; Bouffet E; Pomeroy SL; Marra M; Malkin D; Rutka JT; Korshunov A; Pfister S; Taylor MD
Acta Neuropathol; 2012 Apr; 123(4):615-26. PubMed ID: 22057785
[TBL] [Abstract][Full Text] [Related]
7. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
8. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
9. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
Wang Y; Huang J; Yin X; Xu Q; Sun Y; Yao Y; Xiong J
Acta Neurochir (Wien); 2024 Feb; 166(1):72. PubMed ID: 38329556
[TBL] [Abstract][Full Text] [Related]
12. Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study.
Delaidelli A; Dunham C; Santi M; Negri GL; Triscott J; Zheludkova O; Golanov A; Ryzhova M; Okonechnikov K; Schrimpf D; Stichel D; Ellison DW; von Deimling A; Kool M; Pfister SM; Ramaswamy V; Korshunov A; Taylor MD; Sorensen PH
Clin Cancer Res; 2022 Jan; 28(1):116-128. PubMed ID: 34702771
[TBL] [Abstract][Full Text] [Related]
13. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
14. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
Yeo KK; Margol AS; Kennedy RJ; Hung L; Robison NJ; Dhall G; Asgharzadeh S
J Neurooncol; 2019 Nov; 145(2):375-383. PubMed ID: 31621042
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
17. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
18. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
19. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
20. Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country.
Amayiri N; Swaidan M; Ibrahimi A; Hirmas N; Musharbash A; Bouffet E; Al-Hussaini M; Ramaswamy V
JCO Glob Oncol; 2021 Sep; 7():1442-1453. PubMed ID: 34609903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
